Eledon Pharmaceuticals, Inc. is rated a Strong Buy following positive phase 2 BESTOW results for tegoprubart. Read more on ELDN stock here.

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of FDA-approved C3 inhibitors that targets the root of the complement system can ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Please provide your email address to receive an email when new articles are posted on . Higher measured GFR before bariatric surgery was linked to greater GFR reductions after surgery. Combined ...

Autophagy dysregulation plays an important role in the development and progression of lupus nephritis (LN). However, the key autophagy-related genes involved in LN and their underlying cellular ...

Hello. It's Mark Kris, from Memorial Sloan Kettering. I'm about to say some things that will not make everyone happy. I would like to comment on a recently published article in The New England Journal ...

Calcium (Ca 2+) drives many cellular functions, though the way it controls quality of proteins in the endoplasmic reticulum (ER), a cellular organelle that synthesizes and transports proteins, has not ...

At its December meeting, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion for Aumseqa (aumolertinib mesylate, SFL Pharmaceuticals ...